Skip to main content
Premium Trial:

Request an Annual Quote

Cobb Invests $1M in Roslin Institute for Poultry Genomics Partnership

NEW YORK (GenomeWeb News) – Poultry genetics company Cobb-Vantress will partner with and provide nearly $1 million to The Roslin Institute at the University of Edinburgh to support avian genomics research projects, the partners said yesterday.

Under the three-year agreement, the partners will collaborate on research into avian disease resistance, genome analysis, and genome preservation.

Roslin opened a National Avian Research Facility (NARF) in 2013, funded by the Roslin Foundation, the University of Edinburgh, and the UK government. The NARF is focused on studying a range of diseases that impact poultry food producers, such as Campylobacter and Salmonella, and conducting research for the production of genetically modified chickens.

Roslin and Cobb will undertake several projects to study DNA markers in avian genomes to target traits that are difficult to select for such as immunity, disease tolerance, and disease resistance.

In another project, the partners will develop tools that enable pedigrees or heritage lines to be maintained without having to physically maintain the bird stock.

Cobb's Chief Technology Officer Christine Daugherty said in a statement that the company aims to better understand poultry genomes so it can breed "more robust chickens that will withstand disease and environmental challenges. We're looking for birds with greater immunity to diseases or with the ability to tolerate disease without affecting performance."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.